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We recently reported that zacopride is a selective inward rectifier potassium current (IK1) channel agonist, suppressing ventric-
ular arrhythmias without affecting atrial arrhythmias. The present study aimed to investigate the unique pharmacological prop-
erties of zacopride. The whole-cell patch-clamp technique was used to study IK1 currents in rat atrial myocytes and Kir2.x cur-
rents in human embryonic kidney (HEK)-293 cells transfected with inward rectifier potassium channel (Kir)2.1, Kir2.2, Kir2.3, 
or mutated Kir2.1 (at phosphorylation site S425L). Western immunoblots were performed to estimate the relative protein ex-
pression levels of Kir2.x in rat atria and ventricles. Results showed that zacopride did not affect the IK1 and transmembrane 
potential of atrial myocytes. In HEK293 cells, zacopride increased Kir2.1 homomeric channels by 40.7%±9.7% at 50 mV, but 
did not affect Kir2.2 and Kir2.3 homomeric channels, and Kir2.1-Kir2.2, Kir2.1-Kir2.3 and Kir2.2-Kir2.3 heteromeric chan-
nels. Western immunoblots showed that similar levels of Kir2.3 protein were expressed in rat atria and ventricles, but atrial 
Kir2.1 protein level was only 25% of that measured in the ventricle. In addition, 5-hydroxytryptamine (5-HT)3 receptor was 
undetectable, whereas 5-HT4 receptor was weakly expressed in HEK293 cells. The Kir2.1-activating effect of zacopride in 
these cells was abolished by inhibition of protein kinase A (PKA), but not PKC or PKG. Furthermore, zacopride did not acti-
vate the mutant Kir2.1 channel in HEK293 cells but selectively activated the Kir2.1 homomeric channel via a PKA-dependent 
pathway, independent to that of the 5-HT receptor. 
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Past studies have gone to great efforts in the search for se-
lective inward rectifier potassium current/channel (IK1) 
channel agonists for their anti-ventricular arrhythmia poten-
tial [1]. However, non-selectivity of agonists for multiple 
ion channels and/or receptors may thus induce differential 
effects on arrhythmogenesis in the atria and ventricles. 
Zacopride, a potent 5-hydroxytryptamine (5-HT)3 receptor 
antagonist and 5-HT4 receptor agonist has been experimen-
tally used as a gastrointestinal prokinetic agent [2]. We have 
recently shown that zacopride is also a selective IK1 channel 
agonist in rat ventricular myocytes, moderately increasing 
the IK1 current, hyperpolarizing the resting membrane poten-
tial (RMP), and shortening the action potential duration 
(APD) without affecting other channels, transporters, and 
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pumps [3]. Furthermore, zacopride suppressed the trigger of 
ventricular arrhythmias, but did not affect the electrophysi-
ology of the atria [3]. To our knowledge, this is the first 
discovered agonist with high selectivity for the IK1 channel, 
thus the advantage of an anti-ventricular arrhythmia effect 
but with only minimal adverse effects on the atria. 
Although zacopride was shown to exert an antiarrhyth-
mic action in the ventricles via IK1 channels [3], its potential 
adverse effect on atrial electrophysiology should be taken 
into account. Activation of 5-HT4 receptors by zacopride in 
human atria may result in atrial fibrillation (AF) due to cal-
cium overload and activation of the pacemaker current (If) 
[4–6]. Up-regulation of IK1 in atrial myocytes may also lead 
to AF [7–9]. Despite its selectivity for both 5-HT4 and the 
IK1 channel, zacopride does not induce atrial arrhythmia for 
treatment against triggered ventricular arrhythmia in the rat 
[3] or rabbit (unpublished data by our group). The mecha-
nism underlying this lack of effect is poorly understood.  
Inward rectifier potassium channel (Kir)2.1 (KCNJ2), 
Kir2.2 (KCNJ12) and Kir2.3 (KCNJ4) channels assemble as 
homotetramers or heterotetramers, and are the molecular 
basis of the native pore-forming subunit of IK1 channels in 
the heart [10,11]. Tissue- and species-specific expression 
profiles of Kir2.x isoforms determine the biophysical and 
physiological characteristics of IK1 channels in the heart. 
Moreover, all of the Kir2.x channels, including Kir2.1, 
Kir2.2 and Kir2.3, are the substrates of protein kinase A 
(PKA) and protein kinase C (PKC). Phosphorylation of 
these channel pore-forming proteins may thus play im-
portant regulatory roles in IK1 function [12]. We therefore 
hypothesized that zacopride may exert differential effects 
on atrial and ventricular IK1 through selective actions on 
different Kir2.x channels via phosphorylation, rather than 
the 5-HT receptor. This signaling pathway may serve as a 
mechanism by which zacopride suppresses ventricular ar-
rhythmias without inducing atrial arrhythmias [3]. There-
fore, the present study aimed to investigate the agonist 
properties of zacopride on the IK1 channels.  
In the current study we investigated the effects of 
zacopride on IK1 channels in rat atrial myocytes. Further-
more, to determine the Kir2.x channel and the signaling 
pathway that is selectively activated by zacopride, we ob-
served the effects of this agonist on the homotetramer or 
heterotetrameric channels of Kir2.1, Kir2.2, Kir2.3, or a 
mutant Kir2.1 channel transfected in human embryonic 
kidney (HEK)-293 cells. Our findings showed that 
zacopride increased IK1 in ventricular but not atrial myo-
cytes, and this specific action was due to the selective acti-
vation of Kir2.1 via PKA, but not PKC, protein kinase G 
(PKG), and the 5-HT receptor.  
1  Materials and methods 
1.1  Animals 
Male Sprague Dawley (SD) rats (220–250 g) were provided 
by the Experimental Animal Center (Hebei, China). Animal 
care, surgery, and handling procedures were approved by 
the Bioethical Committee of Shanxi Medical University, 
and performed according to the guidelines for the Care and 
Use of Laboratory Animals (National Institutes of Health 
No. 85-23, revised 1996). Rats were heparinized (1000 U 
kg1, intraperitoneally (i.p.)) and anesthetized with sodium 
pentobarbital (65 mg kg1, i.p.) in all experiments.  
1.2  Isolation of cardiomyocytes  
Isolated atrial myocytes were used for electrophysiological 
studies. They were isolated from rat heart by collagenase 
digestion [13,14]. Briefly, the heart was harvested under 
anesthesia and perfused with oxygenated calcium-free 
Tyrode’s solution (135 mmol L1 NaCl, 5.4 mmol L1 KCl, 
1.8 mmol L1 CaCl2, 1 mmol L1 MgCl2, 0.33 mmol L1 
NaH2PO4, 10 mmol L
1 HEPES, 10 mmol L1 glucose 10; 
pH 7.3–7.4) at 37°C for approximately 7–8 min, followed 
by a 15 min perfusion with Tyrode’s solution containing 
100 mg L1 collagenase P (Boehringer, Mannheim, Germa-
ny). Afterward, the atrium was separated, minced in KB 
solution (85 mmol L1 KOH, 50 mmol L1 L-glutamic acid, 
30 mmol L1 KCl, 1 mmol L1 MgCl2, 30 mmol L1 
KH2PO4, 10 mmol L
1 glucose, 20 mmol L1 taurine, 10 
mmol L1 HEPES, 0.5 mmol L1 EGTA; pH 7.4) and fil-
trated. 
1.3  Cell transfection of Kir2.x 
Respective rat cardiac orthologs of Kir2.1, Kir2.2 and 
Kir2.3 were cloned by reverse transcriptase polymerase 
chain reaction. S425L mutation of the Kir2.1-encoding gene, 
KCNJ2, was introduced by site-directed mutagenesis. Re-
spective cDNAs encoding Kir2.1, Kir2.2, Kir2.3 and a 
Kir2.1 mutant (S425L) [12,15] were subcloned into the eu-
karyotic expression vector, pEGFP-N1. HEK293 cells were 
cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum. Expression plasmids 
were then transfected into confluent HEK293 cells using the 
Lipofectamine 2000 kit (Invitrogen, USA).  
1.4  Electrophysiology 
Whole-cell recordings were performed using the Axopatch 
200B amplifier (Axon Instrument, USA) with a sampling 
rate of 10 kHz, and filtered at 2 kHz. The electrodes were 
filled with pipette solution, and electrode resistance main-
tained at 2–5 M. All experiments were conducted at room 
temperature (23–25°C). Transfected HEK293 cells ex-
pressing enhanced green fluorescent protein (EGFP) were 
viewed under a xenon arc lamp (488/530 nm; excita-
tion/emission, respectively), and selected for the patch 
clamp study. The standard bath solution used in this experi-
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ment was 136 mmol L1 NaCl, 5 mmol L1 KCl, 1.8 mmol L1 
CaCl2, 1 mmol L
1 MgCl2, 10 mmol L1 glucose, and 10 
mmol L1 HEPES (pH 7.4). The standard pipette solution 
used in this study was 40 mmol L1 KCl, 80 mmol L1 
K-aspartate, 10 mmol L1 KH2PO4, 3 mmol L1 phospho-
creatine, 5 mmol L1 EGTA, 5 mmol L1 HEPES, and 5 
mmol L1 ATP-Mg (pH 7.2). To record native atrial IK1, the 
extracellular solution was similar to that used for transfected 
cells, except that 0.2 mmol L1 CdCl2 was added to block 
L-Ca+ channel. For native atrial IK1 recordings, pipette solu-
tion (5 mmol L1 EGTA, 150 mmol L1 KCl, 3 mmol L1 
K2-ATP, 5 mmol L
1 HEPES, 5 mmol L1 4-AP, 1 mmol 
L1 MgCl2, 1 mmol L1 Mg-ATP; pH 7.3) was used. 
Zacopride, RS23597-190 (5-HT4 receptor antagonist), 
PBT (selective 5-HT4 receptor agonist), KT5720 (PKA in-
hibitor), KT5823 (PKG inhibitor), and forskolin (adenylate 
cyclase activator) were purchased from Tocris Cookson Inc. 
(UK). GF109203X (PKC inhibitor) and 8-bromo-cAMP 
were from Sigma-Aldrich (USA). 2-1-(4-Piperonyl) piper-
azinylbenzothiazole (PBT), a known selective 5-HT4 recep-
tor agonist was also purchased from Sigma-Aldrich. 
1.5  Western immunoblotting 
The following primary antibodies were used: monoclonal 
Anti-KCNJ2 antibody produced in mouse, monoclonal An-
ti-KCNJ12 antibody produced in mouse and monoclonal 
Anti-KCNJ4 antibody produced in mouse. They were all 
from Sigma-Aldrich (USA). Anti-5HT3A receptor antibody 
and anti-5HT4 receptor antibody were purchased from 
Abcam (UK). 
Rat brain or heart protein were lysed by solution con-
taining l mmol L1 phenylmethanesulfonyl fluoride (pH 7.4) 
and separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis on 10% polyacrylamide-Tris gels (Sig-
ma-Aldrich, USA), and then transferred electrophoretically 
(2 mA cm2, 20 min) to polyvinylidene fluoride membranes 
(Sigma-Aldrich, USA) with 120 V voltage for 2 h. Mem-
branes were blocked by solution containing 5% (w/v) skim 
milk powder and 0.1% Tween 20 in Tris-buffered saline for 
2 h at room temperature and then incubated (4°C, overnight) 
with the primary antibodies (1:1000 dilution). Membranes 
were then incubated (2 h, at room temperature) with horse-
radish peroxidase-conjugated secondary antibodies (1:1000 
dilution, from Santa Cruz Biotechnology, USA), and bands 
were visualized using enhanced chemiluminescence kit 
(Beyotime Institute of Biotechnology, China).  
1.6  Statistical analyses  
Data are expressed as mean±SEM, and were analyzed by 
the paired t test, or one-way ANOVA followed by least-    
significant difference test. Significance was reached at val-
ues of P<0.05 or P<0.01. 
2  Results 
2.1  Zacopride does not affect the IK1 of rat atrial myo-
cytes  
Original IK1 current tracings (Figure 1A) and the respective 
current-voltage (I-V) curves (Figure 1B) were obtained from 
isolated atrial myocytes with or without 1 mol L1 
zacopride. Zacopride did not significantly modify the in-
ward (at 110 mV; n=6) or outward (at 50 mV; n=6) 
components of the IK1 current. Application of zacopride did 
not affect the RMP or APD (n=5) (Figure 1C). These results 
indicate that zacopride does not affect the atrial IK1 and ac-
tion potential.  
2.2  Kir2.1 and Kir2.3 are the major Kir2.x isoforms in 
rat ventricles and atria  
Western immunoblots and densitometric analysis revealed 
that despite the expression of all Kir2.x isoforms in the ven-
tricles and atria, Kir2.1 was the isoform predominantly ex-
pressed in the ventricles, whereas Kir2.3 was the major iso-
form in the atria (Figure 1D). Kir2.3 was similarly ex-
pressed in both the atria and ventricles. However, level of 
Kir2.1 in the atria was only 25% of that in the ventricle.  
2.3  Zacopride activates Kir2.1 but not Kir2.2 or Kir2.3 
channels in HEK293 cells  
Because zacopride affects IK1 only in the ventricles, and the 
compositions of Kir2.x tetramers are different between atria 
and ventricles [10,11], we thus hypothesized that zacopride 
may be selective for one of the Kir2.x channels. Results 
indicated that zacopride significantly (P<0.01) increased the 
outward component of IKir2.1 by 40.7%±9.7% at 50 mV 
compared with baseline (n=6) (Figure 2A), but did not af-
fect the inward component (9.6%±4.2% at 110 mV; n=6) 
(Figures 2B). The half maximal effective concentration was 
determined as 30.7 mol L1. 
Despite its significant (P<0.01) agonist effect on Kir2.1 
channels (Figure 3A), zacopride did not affect the currents 
of Kir2.2 (3.6%±6.4% at 50 mV; n=5) (Figure 3B) or 
Kir2.3 (1.9%±0.5% at 50 mV; n=4) (Figure 3F). Several 
reports have concluded that both heteromeric and homo-
meric assembly of Kir2.x channels are the basis of native 
IK1 [16–18]. We have previously observed the effects of 
zacopride on cells co-transfected with heteromers of 
Kir2.1/Kir2.2, Kir2.2/Kir2.3, or Kir2.1/Kir2.3 [19]. Our 
results showed that zacopride did not induce an effect on the 
inward or outward components of the heteromeric channels, 
Kir2.1/Kir2.2, Kir2.2/Kir2.3, or Kir2.1/Kir2.3 (Figures 
3D–F, respectively). These results suggested that zacopride 
exerted a significant agonist effect on only Kir2.1 homo-
meric channels.  
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Figure 1  Whole cell recordings of IK1 currents and the expression profile of Kir2.x in rat atria and ventricles. A, Atrial IK1 current traces recorded at a 
holding potential of 40 mV and 500 ms voltage steps ranging from 120 to 20 mV with or without zacopride (1 mol L1). B, I-V curves for atrial IK1 be-
fore and after addition of zacopride and BaCl2 (1 mol L1). All currents were normalized for cell capacitance. C, Effect of zacopride on the AP of isolated 
rat atrial myocytes. D, Western immunoblots and densitometric analysis of Kir2.x proteins in rat atria and ventricles. *, P<0.05 vs. atria. 
2.4  Zacopride regulates the IK1 channel via a 5-HT 
receptor-independent pathway 
We next investigated the possibility that zacopride affects 
the Kir2.1 channel independently from native 5-HT3 and 
5-HT4 receptors in the HEK293 cells. Western immunoblots 
revealed relatively low protein expression of 5-HT4, where-
as 5-HT3 was undetectable (however, both receptors were 
expressed in rat brain and heart) (Figure 4). 
We also examined the effect of a direct activation of 
5-HT4 receptors using PBT (selective 5-HT4 receptor ago-
nist) on the activation of Kir2.1 channels in HEK293 cells. 
Compared with baseline, 100 mol L1 PBT did not show 
an effect on the outward component of IKir2.1 at 50 mV 
(10.5%±4.2%; n=4) (Figure 5A). However, PBT signifi-
cantly (P<0.05) decreased the inward IKir2.1 by 31.4%±8.6% 
at 110 mV (n=4) (Figure 5B), indicating that zacopride 
may not activate Kir2.1 via the 5-HT4 receptor. Considering 
that the 5-HT3 receptor was undetectable in HEK293 cells 
(Figure 4A), the above observations strongly support the 
selectivity of zacopride for the Kir2.1 channel, independent 
of the 5-HT receptor. 
We next sought to determine whether 5-HT4 receptors 
influenced the IK1 response mediated by zacopride, using 
RS23597-190 (5-HT4 receptor antagonist). A mean I-V  
relationship for IKir2.1 was recorded in Kir2.1-transfected 
HEK293 cells with or without a 5 min exposure of 
RS23597-190, alone or with zacopride. RS23597-190 alone 
did not affect the IKir2.1 response compared with control 
(Figure 5C). Furthermore, RS23597-190 did not affect the 
enhanced response of IKir2.1 by zacopride (Figure 5C).  
2.5  Zacopride increases Kir2.1 currents via the 
PKA-mediated signaling pathway 
To elucidate the key signaling pathway(s) by which 
zacopride activates Kir2.1 channels, we investigated the 
effects of various protein kinase inhibitors on the zacopride-     
mediated responses via Kir2.1 in HEK293 cells. HEK293 
cells were pretreated with each of these protein kinase in- 
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Figure 2  Zacopride increases Kir2.1 currents in transiently transfected 
HEK293 cells. A, Kir2.1 current traces recorded at a holding potential of 
40 mV and 500 ms voltage steps ranging from 120 to 20 mV with or 
without zacopride. B, I-V curves for Kir2.1 before and after addition of 
zacopride, and data at potentials positive to EK in an expanded scale (inset 
graph). C, Changes of IKir2.1 at different concentrations of zacopride meas-
ured at 50 mV. *, P<0.05; **, P<0.01 vs. control. 
hibitors for 5 min before applying zacopride. Compared 
with baseline, zacopride alone significantly (P<0.05)   
increased the outward Kir2.1 current by 40.7%±9.7% at   
50 mV (n=6) (Figures 2B and C). However, in the presence 
of KT5720, this response was diminished (Figures 2B, C and 
6A) (P>0.05). In contrast, GF109203X or KT5823 did not 
significantly alter zacopride-mediated activation of Kir2.1 
(Figures 6B and C). These results indicated that inhibition 
PKA activation, but not that of PKC or PKG, abolished the 
agonist-mediated effect of zacopride on Kir2.1 current. 
We next aimed to determine the effect of adenylyl 
cyclase activation on the activity of Kir2.1 channels ex-
pressed in HEK293 cells. Compared with baseline, for-
skolin (Figure 7A) or 8-bromo-cAMP (Figure 7B) signifi-
cantly enhanced Kir2.1 currents at 50 mV, by 24.1%± 
5.9% (P<0.01) or 22.1%±1.9% (P<0.05), respectively. 
These data support our hypothesis that zacopride activates 
the Kir2.1 channel via a PKA-dependent pathway.  
2.6  PKA-mediated phosphorylation of Kir2.1 is in-
volved in zacopride-induced activation of Kir2.1 chan-
nels  
Based on the finding that zacopride activated Kir2.1 chan-
nels via a PKA-dependent pathway, we thus hypothesized 
that it may induce the phosphorylation of Kir2.1 via PKA. 
In mutant Kir2.1 (Kir2.1(S425L)) HEK293 cells, zacopride 
did not significantly increase IKir2.1(S425L) at 50 mV com-
pared with control (Figure 7C). This result indicated that 
inhibition of the PKA phosphorylation site almost com-
pletely abolished the agonist effect of zacopride on Kir2.1. 
Thus, the selective activation of Kir2.1 channel by  
 
Figure 3  Zacopride does not affect Kir2.2 and Kir2.3 currents in transiently transfected HEK293 cells. I-V curves for the (A) Kir2.2 or (B) Kir2.3 homo-
meric channels, and the (C) Kir2.1-Kir2.2, (D) Kir2.1-Kir2.3, or (E) Kir2.2-Kir2.3 heteromeric channels, with or without zacopride. F, Bar graphs showing 
the differential effects of zacopride on Kir2.x currents measured at 50 mV (data for Kir2.1 are from Figure 2). **, P<0.01 vs. IKir2.1. 
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Figure 4  Protein expression profile 5-HT receptors in different tissues. 
Western immunoblot analysis of (A) 5-HT3 receptor and (B) 5-HT4 recep-
tor in rat brain, heart, and HEK293 cells.  
zacopride may occur primarily via PKA-mediated phos-
phorylation of this channel.  
3  Discussion 
In the present study, we demonstrate for the first time that 
zacopride, a recently approved selective IK1 channel agonist, 
increases IK1 current in myocytes of ventricles but not of 
atria. This finding is corroborated by further results showing 
that zacopride selectively activates the Kir2.1 channel, 
which was found to be the predominant isoform of IK1 
channel in the ventricles but not atria. We also show that the 
agonist action of zacopride on Kir2.1 channels is via a 
PKA-dependent but 5-HT receptor-independent pathway, 
and that its induced activation of the Kir2.1 channel is pre-
dominantly via the PKA-mediated phosphorylation of Kir2.1. 
Overall, zacopride suppresses triggered ventricular ar-
rhythmias while exhibiting no adverse effects on atrial elec-
trophysiology. These findings may thus provide a deeper 
insight into the molecular basis underlying the unique prop-
erties of zacopride as a myocardial IK1 agonist. 
Our group has recently demonstrated that zacopride pre-
vents or eliminates aconitine (toxin)-induced ventricular 
arrhythmias in rat, because of the enhancement of IK1 [3]. 
Activation of atrial IK1 current is well known to be a poten-
tial cause of AF [7–9]. Therefore, potential adverse effects 
on atrial electrophysiology should be considered during 
zacopride treatment for triggered ventricular arrhythmias. 
However, the present study showed that in contrast to its 
significant effects on the RP and APD in ventricular myo-
cytes, zacopride did not modify the RP and APD of rat atrial 
myocytes. Tissue-specific activation of IK1 by zacopride 
may thus account for the above differential actions on ven-
tricles and atria, and this may further explain why zacopride 
did not induce AF in our previous study [3]. Tissue and 
species-specific expression profiles of Kir2.x isoforms have 
determined the biophysical and regulatory properties of IK1 
in the heart [10,11]. Western immunoblots of the present 
study showed that all Kir2x isoforms were expressed in the 
rat heart, with Kir2.1 and Kir2.3 the predominant isoform 
expressed in the ventricle and atria, respectively. However, 
atrial Kir2.1 protein level was only 25% of that measured in 
the ventricle. Several reports have concluded that both het-
eromeric and homomeric assemblies of Kir2.x channels are 
the basis of native IK1 [16–18]. In the present study, 
zacopride selectively activated Kir2.1 but not Kir2.2 or  
 
 
Figure 5  Function of 5-HT receptors in the IK1-agonist effect by zacopride in HEK293 cells. A, Kir2.1 current traces recorded in transiently transfected 
HEK293 cells at 40 mV and 500 ms voltage steps ranging from 120 to 20 mV with or without PBT (100 mol L1). B and C, Respective I-V curves for 
IKir2.1 for 5-HT4 receptor agonist, 5-HT3 receptor antagonist and zacopride treatments, and data at potentials positive to EK in an expanded scale (inset graph). 
*, P<0.05 vs. control. 
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Figure 6  Zacopride increases Kir2.1 currents via a PKA-mediated sig-
naling pathway. I-V curves for IKir2.1 recorded in HEK293 cells before and 
after a 5 min exposure to (A) KT5720 or KT5720 (both 5 mol L1) with 
zacopride, (B) KT5823 or KT5823 (both 5 mol L1) with zacopride, or (C) 
GF109203X or GF109203X (both 5 mol L1) with zacopride. Inset graph, 
data at potentials positive to EK in an expanded scale. D, Outward incre-
ment of IKir2.1 following application of protein kinase inhibitors with 
zacopride. *, P<0.05 vs. protein kinase inhibitors alone; #, P<0.05 vs. 
zacopride alone. 
Kir2.3, and this effect was only found in Kir2.1 homo-
tetrameric channels. Therefore, zacopride-mediated effect 
on IK1 may only occur in those species and/or tissues in 
which IK1 is mainly generated by Kir2.1 homotetrameric 
channels. Our present pharmacological findings suggest that 
rat atrial IK1 is mainly generated by Kir2.3 homotetrameric 
channels and/or Kir2.x (including Kir2.1) heterotetrameric 
channels. Furthermore, these channels are predominantly 
unaffected by zacopride, and thus may explain the increase 
of IK1 in only ventricles.  
Our previous study using zacopride revealed that 1 mol 
L1 was the optimal concentration to increase both the in-
ward and outward components of the IK1 in rat ventricular 
myocytes [3]. However, in the present study, the effect of 
zacopride on Kir2.1 was different to the IK1 of native Kir2x 
in cardiomyocytes. First, the concentration of zacopride to 
achieve a maximal efficacy for the activation of Kir2.1 was 
much higher in HEK293 cells (100 mol L1) than in ven-
tricular myocytes (1 mol L1) [3]. Second, our current 
findings showed that zacopride enhanced only the outward 
IKir2.1 in HEK293 cells, whereas it enhances both inward and 
outward components of IK1 in native ventricular myocytes 
[3]. One possibility for this phenomenon is that the heterol-
ogous expression system may not reproduce the sophisti-
cated cellular environment of native cells [20], including the 
accessory subunits and regulatory proteins of the IK1 chan-
nel that are linked to the intracellular cytoskeleton and to 
the extracellular matrix. Although the effects of these ac-
cessory proteins do not completely change the direct action 
of drugs, care must be taken when extrapolating the data 
obtained from heterologous expression systems to native 
cells [21]. A previous study suggests that Kir2.1 interacts 
with A kinase-anchoring protein 79 (AKAP79), and the 
presence of AKAP79 enhances the response of Kir2.1 to 
elevated intracellular cyclic adenosine monophosphate 
(cAMP) [22]. Therefore, in the present study, AKAP79 
protein expression (via Western immunoblotting) was ex-
amined in HEK293 cells and rat heart. Results showed that 
the expression level of AKAP79 was 4-fold higher in the rat 
ventricle than in HEK293 cells (data not shown). This result 
may help explain the higher sensitivity of zacopride to na-
tive (i.e., ventricular) cells than HEK293 cells in IK1 chan-
nel-PKA signaling.  
 
 
Figure 7  PKA-mediated phosphorylation of Kir2.1 is involved in zacopride-induced activation of Kir2.1 channels. I-V curves for IKir2.1 before and after 
addition of (A) forskolin (50 mol L1), or (B) 8-bromo-cAMP (50 mol L1). Inset graph, data at potentials positive to EK in an expanded scale. C, I-V 
curves for IKir2.1 S425L before and after addition of zacopride. *, P<0.05 vs. control. 
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Zacopride may enhance Kir2.1 currents by blocking 
5-HT3 receptors or activating 5-HT4 receptors via its antag-
onist or agonist effects, respectively. However, the present 
study has shown that in HEK293 cells, endogenous 5-HT3 
receptors are not expressed, while endogenous 5-HT4 is ex-
pressed at very low levels. Our findings also indicated that 
PBT (5-HT4 receptor agonist) did not affect the outward 
Kir2.1 component but inhibited the inward Kir2.1 current. 
In addition, RS23597-190 (5-HT4 receptor antagonist), did 
not affect zacopride-mediated activation of Kir2.1. These 
findings strongly suggest that zacopride regulates IK1 via a 
5-HT receptor-independent pathway.  
The Kir2.1 channel has been shown to be differentially 
regulated by protein kinases, including PKA and PKC [12]. 
Furthermore, the Kir2.1 channel is rather sensitive to 
PKA-dependent regulation [10,12,15]. In the present study, 
blocking PKA signaling inhibited zacopride-mediated en-
hancement of the Kir2.1 current, and PKC or PKG inhibi-
tion did not have an effect. Therefore, the results suggested 
that enhancement of Kir2.1 current by zacopride may be 
PKA-dependent. Recent studies have provided inconsistent 
results regarding the effect of PKA on modulating the activ-
ity of the Kir2.1 channel. For example, cAMP was shown to 
increase Kir2.1 currents in CHO cells [22], and activation of 
PKA resulted in an inhibitory effect on Kir2.1 and homo-
meric Kir2.1 currents, in xenopus oocytes [23] and COS-7 
cells [15], respectively. Our current findings revealed that 
forskolin or 8-bromo-cAMP activated Kir2.1 in HEK293 
cells. Overall, these discrepancies may, at least in part, re-
sult from different heterologous expression systems used, 
because numerous model lines may differ in their expres-
sion of proteins or in the cross-talk of signaling pathways.  
Modulation of ion channel activity through protein 
phosphorylation is an important physiological control mech-
anism. In Kir2.1, Kir2.2 and Kir2.3 subunits, the PKA phos-
phorylation motif is present at the serine residue near the 
COOH terminus [12,24]. The present study revealed that the 
activation of the Kir2.1S425L channel by zacopride was lost, 
thereby providing further solid evidence that the IKir2.1-      
enhancing effect of zacopride was dependent on the phos-
phorylation of Kir2.1 at the single PKA consensus site 
(ser-425). However, this study was not able to detect the 
membrane receptor of zacopride. Future studies may help 
resolve this issue.  
In conclusion, the present study demonstrates that 
zacopride selectively activates the homomeric Kir2.1 chan-
nel via a PKA-mediated signaling pathway. This finding 
may suggest an important mechanism by which zacopride 
exerts an IK1 agonist effect in the ventricle but not atrium. 
This unique feature of zacopride suggests that its potential 
risk to induce AF may be overestimated when used as a 
drug against ventricular arrhythmia. Therefore, this study 
may shed light on the development of IK1 channel agonists 
as anti-arrhythmia drugs.  
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